论文部分内容阅读
本文对９名高脂血症患者及９名健康志愿者进行了单剂量口服甲硝唑６００ｍｇ的唾液药代动力学对比研究，以探讨高脂血症患者服用甲硝唑后ＡＤＲｓ出现率高的原因；结果为：两组甲硝唑药时曲线均符合一室开放模型。结果为高血脂组：Ｔｐ为１．１５±１．２０ｈ；Ｃｍａｘ为１４．０２±１．５４ｍｇ·Ｌ－１；Ｔ１／２ｋｅ为１２．９１±６．３０ｈ；ＡＵＣ为２７２．２４±８２．８５μｇ·ｈ·Ｌ－１。正常组：Ｔｐ为２．２０４±１．５３ｈ；Ｃｍａｘ为１０．３５±２．７７ｍｇ·Ｌ－１；Ｔ１／２Ｋｅ为８．０７±４．２８ｈ；ＡＵＣ为１５４．４３±６９．４１μｇ·ｈ·Ｌ－１。两组之间Ｔ检验差异显著，高脂血症者对甲硝唑吸收快、达峰快、吸收量多、代谢排泄慢、Ｔ１／２延长、ＡＵＣ明显增大造成体内药物浓度高。结果表明临床高脂血症患者用甲硝唑后的药物不良反应多且严重的原因。
In this paper, nine patients with hyperlipidemia and nine healthy volunteers were given a single oral dose of metronidazole 600mg saliva pharmacokinetics comparative study to explore the hyperlipidemia patients taking metronidazole ADRs high incidence The reason was that the curves of metronidazole in both groups were in accordance with the one-compartment open model. The results for the hyperlipidemia group: Tp was 1.15 ± 1.20h; Cmax was 14.02 ± 1.54mg · L-1; T1 / 2ke was 12.91 ± 6.30h; AUC was 272.24 ± 82. 85μg · h · L-1. The normal group: Tp was 2.204 ± 1.53h; Cmax was 10.35 ± 2.77mg · L-1; T1 / 2Ke was 8.07 ± 4.28h; AUC was 154.43 ± 69.41μg · h · L-1. T test between the two groups significant difference, hyperlipidemia who metronidazole fast absorption, peak fast, absorption and metabolism excretion slow, T1 / 2 extended, AUC significantly increased the body caused by high drug concentration. The results showed that patients with clinical hyperlipidemia with metronidazole adverse reactions and more serious reasons.